The company had a dispiriting update to offer about an investigational drug. For the second trading session in less than a week, Roche Holding (RHHBY -6.02%) stock really took it on the chin Wednesday. Dispiriting news about its investigational obesity drug was the culprit; disseminating this, investors sold out of the pharmaceutical veteran. At the end of the day's action, Roche had lost almost 6% of its value. Obesity drug disappoints In a meeting of the European Association for the Study of Diabetes that ...

10'000 Hours/DigitalVision via Getty Images Investment Overview I last covered the Swiss pharma giant Roche (OTCQX:RHHBY) in a note for Seeking Alpha in mid-May, giving the company's stock a "Buy" recommendation. Shares have risen in value by ~22% since, trading at ~$40 at the time of writing, which translates to a market cap valuation of $254bn. In that note I wrote: Roche has been struggling for top and bottom line growth over the past several years, and this may have affected its share price and valuatio ...

Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pathology platform to enhance precision medicine and improve cancer biomarker testing SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AIpowered solutions for cancer diagnostics and therapeutics, today announced its collaboration with Roche to integrate Lunit SCOPE PD-L1 22C3 TPS into Roche's navify® Digital Pathology platform. This marks the first deployment of Lunit's ...

For Immediate Releases Chicago, IL – September 9, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN) , Roche Holding AG (RHHBY) , GE Aerospace (GE) , Canterbury Park Holding Corp. (CPHC) and NVE Corp. (NVEC) . Here are highlights from Monday's Analyst Blog: Top Analyst Reports for Amazon.com, ...

Core Insights - Stratipath has announced a collaboration with Roche to distribute the Stratipath Breast solution, enhancing breast cancer diagnostics through AI integration [1][4] - Stratipath Breast is the first EU regulatory-compliant AI-based solution for breast cancer risk stratification, providing faster and more cost-effective diagnostics compared to traditional methods [2][3] - The integration with Roche's navify® Digital Pathology software allows pathology labs to access AI-driven prognostic insights, improving efficiency and reducing costs [3][4] Company Overview - Stratipath is a leader in AI-based precision diagnostic solutions, focusing on improving diagnostic evaluations in breast cancer [1][2] - Roche is the world's largest biotechnology company, recognized for its leadership in in vitro diagnostics [1] Industry Impact - The collaboration signifies a major advancement in breast cancer diagnostics, leveraging AI and digital pathology to enhance patient care globally [4] - AI-based risk profiling reduces reliance on expensive molecular testing, making diagnostics more accessible to a larger patient population [2][3]

Core Insights - Roche's investigational BTK inhibitor fenebrutinib shows promising results in treating relapsing multiple sclerosis (RMS), with 96% of patients free from relapses after one year and an annualized relapse rate (ARR) of 0.04 [2][3] - The Phase II FENopta study data indicates that fenebrutinib effectively suppresses disease activity, with 99% of patients free from T1 gadolinium-enhancing lesions after 48 weeks [3][4] - The ongoing Phase III trials aim to further validate fenebrutinib's efficacy and safety across multiple sclerosis types, with results expected by the end of 2025 [5][7] Company Overview - Roche is focused on developing fenebrutinib as a dual inhibitor targeting both B-cell and microglia activation, addressing unmet medical needs in multiple sclerosis [6][7] - The company has treated over 2,700 patients and healthy volunteers with fenebrutinib across various clinical programs, emphasizing its commitment to neuroscience research [7][15] - Roche's ongoing research includes multiple sclerosis and other neurological disorders, aiming to improve treatment outcomes and patient quality of life [14][15] Clinical Study Details - The FENopta study was a global Phase II trial involving 109 adults with RMS, assessing the efficacy, safety, and pharmacokinetics of fenebrutinib [8][9] - Patients who completed the FENopta study were given the option to participate in an open-label extension study, with 96 patients remaining after one year [10] - The study demonstrated that fenebrutinib crosses the blood-brain barrier and significantly reduces new lesions compared to placebo [9][10]

With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregivers Approval is based on COMMODORE 2, where subcutaneous (SC) PiaSky once a month was equivalent to intravenous eculizumab every two weeks1,2 PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration3 Basel, 27 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announc ...

PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) ("LIXTE" or the "Company"), today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute (NKI) and supported by F. Hoffmann-La Roche Ltd. ("Roche") for treatment of unresponsive (MSI Low) metastatic colorectal cancer. As part of the clinical trial (NCT06012734, clinicaltrials.gov), LIXTE is providing its lead compound, LB-100, and R ...

Roche Holding AG (RHHBY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices - - has triggered this rating change. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a changing ...

Core Viewpoint - Roche is actively supporting the global response to the mpox outbreak by providing access to high-quality PCR testing and enhancing laboratory testing capacity worldwide [1][2][3] Group 1: Company Initiatives - Roche has developed a suite of diagnostic tests for mpox, including the cobas MPXV test and LightMix® research use only kits, which detect the latest mpox virus variants [1][3] - The company is collaborating with governments and healthcare providers to improve mpox laboratory capacity globally, including training laboratories in Africa [2][3] - Roche's commitment to mpox response began in 2022, focusing on rapid and high-quality PCR testing to address public health challenges [3][4] Group 2: Product Details - The LightMix Modular Orthopox / Monkeypox Virus Kits were developed in May 2022 to detect Orthopoxviruses, including the mpox virus, using quantitative PCR technology [4][5] - The cobas MPXV test received Emergency Use Authorization from the FDA in November 2022 and is designed for high-throughput testing on cobas 6800/8800 Systems [6][7] Group 3: Background Information - Mpox, previously known as monkeypox, is a viral disease that can spread easily between people and from infected animals, with symptoms including fever, chills, and a painful rash [7] - Roche, founded in 1896, is a leading biotechnology company and global leader in in-vitro diagnostics, focusing on improving healthcare through innovative solutions [8][9]